March 2024
-
03.13.2024 Vaccines Vaccines European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease -
03.12.2024 Medicines Research Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) -
03.05.2024 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 2024
-
02.29.2024 Financial Investments Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth -
02.29.2024 Vaccines Vaccines Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults -
02.26.2024 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference -
02.19.2024 Prescription Medicines Medicines European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis -
02.15.2024 Financial Finance Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day -
02.05.2024 Prescription Medicines Responsibility Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
January 2024
-
01.30.2024 Corporate Financial Finance Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance -
01.26.2024 Prescription Medicines Medicines European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer -
01.10.2024 Financial Finance Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation